Search

Your search keyword '"Caradonna, M."' showing total 13 results
Start Over Author "Caradonna, M." Language english
13 results on '"Caradonna, M."'

2. The role of antitissue transglutaminase assay for the diagnosis and monitoring of coeliac disease: a French-Italian multicentre study. (Original Article)

Author

Tonutti, E., Visentini, D., Bizzaro, N., Caradonna, M., Cerni, L., Villalta, D., and Tozzoli, R.

Subjects
Methodology -- Research, Gastrointestinal diseases -- Research, Health, Research
Abstract

Aims: Tissue transglutaminase (tTG) was recently identified as the major autoantigen in coeliac disease. The aim of this multicentre study was to evaluate the impact of a new immunoenzymatic assay [...]

Published
2003

6. The role of antitissue transglutaminase assay for the diagnosis and monitoring of coeliac disease: A French-Italian multicentre study

Author

Tonutti E., Visentini D., Bizzaro N., Caradonna M., Cerni L., Villalta D., Tozzoli R. F Ferrara, M Barraco, E Migali, D Mariotti, G Danzi, ML Martino, M Danzi, M Baldassarre, G Di Bitonto, M Ciccarelli, D Riello, G Bertiato, G Pedicini, RC Bocchino, F Moccia, G Alessio, P Amboni, C Ottomano, U Volta, A Granito, N Carabellese, R Amato, G Aurnia, C Spagnulo, P Clemen, F Coppola, G Spagnoletti, M Spina, T Trigilia, F Branciforte, L Giancotti, M Apollini, B Malamisura, A Sofia, M Boffardi, F Antico, P Arigliano, G Marcer, E Sala, ML Grassi, G Giana, C Staffa, V Cova, M Martinelli, A Calabrò, D Renzi, D Nigro, D Macchia, M Manfredi, E Cammelli, G Castellucci, L Ferraro, L Marchetti, G Garelli, M Colombo, E Castellano, M Cingolani, A Sabatino, A Di Blasi, M Golato, A Carlucci, G Spagnuolo, G Trivisonno, V Castelli, S Babbini, V Marrè, G Meli, S Amoroso, M Montesanti, E Mei, S Armelloni, C Gerosa, C Marcellino, C Gallo, R Pozzoli, M Peracchi, MT Bardella, C Trovato, VS Arosio, R Malberti, F Rea, MR Di Domenico, A Sergio, P Iardino, V Formicola, G Tamburro, A Massari, M Cirella, E Rondinella, A Pignero, D Scognamiglio, S Spagnuolo, S Orefice, V Romano, B Pennucci, A Maglione, S Lavecchia, A Rubino, O Leone, N Cantieri, F Michelutti, G Guariso, D Basso, S Teresi, E Gucciardino, M Di Gregorio, MA Trippiedi, P Greco, R Guadagna, E Maltese, T Imbastaro, G Lombardi, A Rossi, E Savi, L Spada, D Villalta, G Tabellini, M Saccarola, P Palumbo, G Marinucci, PM Strappini, F Viola, M Barbato, Roma, N Bizzaro, P Pasini, F Minetti, M Scogna, M Vascotto, G Morgese, F Bascietto, P Cantelmi, F Bulacanti, D Bassetti, S Santer, D Prizzon, S Loperfido, S Martelossi, T Not, A Ventura, E Tonutti, D Visentini, S Finazzi, S Salvatore, GV Melzi d’Eril, D Wolf, M Montesanto, M Negri, MG Azzeni, R Giordano, M Farina, S Micieli, V Gouilleux, O Bandin, A Tridon, M Meyer, F Bienvenu, G Beaune, S Jego, M San Marco, D Bernard, J Sarles, J Sahel, D Carre, S Benzaken, JF Demarquay, C Johanet, JJ Baudon., Tonutti E., Visentini D., Bizzaro N., Caradonna M., Cerni L., Villalta D., Tozzoli R. F Ferrara, M Barraco, E Migali, D Mariotti, G Danzi, ML Martino, M Danzi, M Baldassarre, G Di Bitonto, M Ciccarelli, D Riello, G Bertiato, G Pedicini, RC Bocchino, F Moccia, G Alessio, P Amboni, C Ottomano, U Volta, A Granito, N Carabellese, R Amato, G Aurnia, C Spagnulo, P Clemen, F Coppola, G Spagnoletti, M Spina, T Trigilia, F Branciforte, L Giancotti, M Apollini, B Malamisura, A Sofia, M Boffardi, F Antico, P Arigliano, G Marcer, E Sala, ML Grassi, G Giana, C Staffa, V Cova, M Martinelli, A Calabrò, D Renzi, D Nigro, D Macchia, M Manfredi, E Cammelli, G Castellucci, L Ferraro, L Marchetti, G Garelli, M Colombo, E Castellano, M Cingolani, A Sabatino, A Di Blasi, M Golato, A Carlucci, G Spagnuolo, G Trivisonno, V Castelli, S Babbini, V Marrè, G Meli, S Amoroso, M Montesanti, E Mei, S Armelloni, C Gerosa, C Marcellino, C Gallo, R Pozzoli, M Peracchi, MT Bardella, C Trovato, VS Arosio, R Malberti, F Rea, MR Di Domenico, A Sergio, P Iardino, V Formicola, G Tamburro, A Massari, M Cirella, E Rondinella, A Pignero, D Scognamiglio, S Spagnuolo, S Orefice, V Romano, B Pennucci, A Maglione, S Lavecchia, A Rubino, O Leone, N Cantieri, F Michelutti, G Guariso, D Basso, S Teresi, E Gucciardino, M Di Gregorio, MA Trippiedi, P Greco, R Guadagna, E Maltese, T Imbastaro, G Lombardi, A Rossi, E Savi, L Spada, D Villalta, G Tabellini, M Saccarola, P Palumbo, G Marinucci, PM Strappini, F Viola, M Barbato, Roma, and N Bizzaro, P Pasini, F Minetti, M Scogna, M Vascotto, G Morgese, F Bascietto, P Cantelmi, F Bulacanti, D Bassetti, S Santer, D Prizzon, S Loperfido, S Martelossi, T Not, A Ventura, E Tonutti, D Visentini, S Finazzi, S Salvatore, GV Melzi d’Eril, D Wolf, M Montesanto, M Negri, MG Azzeni, R Giordano, M Farina, S Micieli, V Gouilleux, O Bandin, A Tridon, M Meyer, F Bienvenu, G Beaune, S Jego, M San Marco, D Bernard, J Sarles, J Sahel, D Carre, S Benzaken, JF Demarquay, C Johanet, JJ Baudon.

Subjects
Immunoglobulin A, Adult, Male, Adolescent, Tissue transglutaminase, Reproducibility of Result, Enzyme-Linked Immunosorbent Assay, Autoantigens, Sensitivity and Specificity, Coeliac disease, Pathology and Forensic Medicine, Serology, Antigen, Autoantigen, Immunopathology, Humans, Medicine, Age Factor, Child, Autoantibodies, Transglutaminases, biology, business.industry, Age Factors, Reproducibility of Results, Infant, Original Articles, General Medicine, Biomarker, medicine.disease, Autoantibodie, Celiac Disease, Child, Preschool, Immunoglobulin G, Immunology, biology.protein, Gluten free, Female, Antibody, business, Biomarkers, Human
Abstract

Aims: Tissue transglutaminase (tTG) was recently identified as the major autoantigen in coeliac disease. The aim of this multicentre study was to evaluate the impact of a new immunoenzymatic assay for the detection of IgA anti-tGT antibodies. Methods: Seventy four Italian and French clinical laboratories participated in this study; anti-tTG IgA with an enzyme linked immunosorbent assay (ELISA) method using guinea pig liver extract as the coating antigen, anti-endomysium IgA autoantibodies (EMA), and total serum IgA were determined in 7948 patients, 1162 of whom had coeliac disease (737 untreated cases and 425 on a gluten free diet). A proportion of the sera were then sent to a reference laboratory for anti-tTG retesting with an ELISA method using recombinant human tTG antigen. Results: Seven thousand four hundred and fifty eight (93.8%) sera were EMA/antiguinea pig tTG concordant (positive or negative); 490 (6.2%) were non-concordant. The sensitivity of EMA and antiguinea pig tTG in the 737 untreated patients with coeliac disease was 92.1% and 94.8%, respectively, and the specificity was 99.8% and 99.2%, respectively. Retesting of the discordant sera showed that of the 162 sera classified as EMA negative/antiguinea pig tTG positive, only 49 were positive for human recombinant anti-tTG, and that 39 of these were also EMA positive. Furthermore, of the 36 sera classified as EMA positive/antiguinea pig tTG negative, only two were confirmed as EMA positive. Conclusions: The antiguinea pig tTG assay is more sensitive but less specific than EMA, whereas the antihuman recombinant tTG assay is far more specific and just as sensitive as antiguinea pig tTG. Testing for EMA presents considerable interpretative problems and is difficult to standardise.

Published
2003

10. One-year renal and cardiac effects of bisoprolol versus losartan in recently diagnosed hypertensive patients: a randomized, double-blind study

Author

Caterina Trapanese, Giuseppe Licata, Pietro Di Pasquale, Manuela Mezzero, Mauro Cardillo, Gaspare Parrinello, Daniele Torres, Salvatore Paterna, Gabriella La Rocca, Mario Caradonna, Parrinello, G, Paterna, S, Torres, D, Di Pasquale, P, Mezzero, M, La Rocca, G, Cardillo, M, Trapanese, C, Caradonna, M, and Licata, G

Subjects
Adult, Male, medicine.medical_specialty, Time Factors, medicine.drug_class, Renal function, Hemodynamics, Essential hypertension, Kidney, Kidney Function Tests, Losartan, law.invention, Randomized controlled trial, Double-Blind Method, law, Internal medicine, medicine, Bisoprolol, Humans, Pharmacology (medical), Antihypertensive Agents, hypertension, losartan,bisiprolol, business.industry, Heart, General Medicine, Middle Aged, Receptor antagonist, medicine.disease, Angiotensin II, Heart Function Tests, Hypertension, Cardiology, Female, business, medicine.drug
Abstract

BACKGROUND AND OBJECTIVES: Hypertension is a significant cause of chronic renal injury and its effective treatment is capable of reducing the rate of renal failure. beta-Adrenoceptor antagonists (beta-blockers) have been reported to induce a deterioration in renal function, while several data have indicated a renoprotective effect of treatment with the angiotensin II type 1 receptor antagonist losartan. Previous studies of the interaction between the selective beta(1)-blocker bisoprolol and kidney function were performed only for short- and medium-term periods. The aim of this study was to compare the antihypertensive efficacy and renal and cardiac haemodynamic effects of bisoprolol with those of losartan over a 1-year time period in patients with essential hypertension. METHODS: Seventy-two patients (40 males) with recently diagnosed uncomplicated (European Society of Hypertension [ESH] criteria stage 1-2) hypertension (mean +/- SD age 52 +/- 12 years) were enrolled in the study. After a run-in period of 14 days on placebo, the patients were randomized in a double-blind, prospective study to receive either bisoprolol 5 mg or losartan 50 mg, administered once daily for 1 year. At recruitment and 12 months after treatment, cardiac output and renal haemodynamics and function were evaluated by echocardiography and radionuclide studies, respectively. RESULTS: There were no significant differences in baseline clinical data, including glomerular filtration rate and blood pressure, between the two treatment groups. At 1 year, blood pressure had decreased significantly (p < 0.001) with both treatments, and heart rate was reduced only in the group taking bisoprolol. The long-term effects on renal haemodynamics and cardiac function were similar with both drugs, the only change being a significant reduction in the filtration fraction for each group. CONCLUSIONS: These data suggest that both bisoprolol and losartan are effective agents for the treatment of patients with recently diagnosed ESH stage 1-2 hypertension. Over a 1-year period, both agents maintained good renal and cardiac performance and haemodynamics.

Published
2009

11. Exploring the Link between BMI and Aggressive Histopathological Subtypes in Differentiated Thyroid Carcinoma-Insights from a Multicentre Retrospective Study.

Author

Di Filippo G, Canu GL, Lazzari G, Serbusca D, Morelli E, Brazzarola P, Rossi L, Gjeloshi B, Caradonna M, Kotsovolis G, Pliakos I, Poulios E, Papavramidis T, Cappellacci F, Nocini PF, Calò PG, Materazzi G, and Medas F

Abstract

Obesity's role in thyroid cancer development is still debated, as well as its association with aggressive histopathological subtypes (AHSs). To clarify the link between Body Mass Index (BMI) and AHS of differentiated thyroid carcinoma (DTC), we evaluated patients who underwent thyroidectomy for DTC from 2020 to 2022 at four European referral centres for endocrine surgery. Based on BMI, patients were classified as normal-underweight, overweight, or obese. AHSs were defined according to 2022 WHO guidelines. Among 3868 patients included, 34.5% were overweight and 19.6% obese. Histological diagnoses were: 93.6% papillary (PTC), 4.8% follicular (FTC), and 1.6% Hürthle cell (HCC) thyroid carcinoma. Obese and overweight patients with PTC had a higher rate of AHSs ( p = 0.03), bilateral, multifocal tumours ( p = 0.014, 0.049), and larger nodal metastases ( p = 0.017). In a multivariate analysis, BMI was an independent predictor of AHS of PTC, irrespective of gender ( p = 0.028). In younger patients (<55 years old) with PTC > 1 cm, BMI predicted a higher ATA risk class ( p = 0.036). Overweight and obese patients with FTC had larger tumours ( p = 0.036). No difference was found in terms of AHS of FTC and HCC based on BMI category. Overweight and obese patients with PTC appear to be at an increased risk for AHS and aggressive clinico-pathological characteristics.

Published
2024
Full Text
View/download PDF

12. One-year renal and cardiac effects of bisoprolol versus losartan in recently diagnosed hypertensive patients: a randomized, double-blind study.

Author

Parrinello G, Paterna S, Torres D, Di Pasquale P, Mezzero M, La Rocca G, Cardillo M, Trapanese C, Caradonna M, and Licata G

Subjects
Adult, Antihypertensive Agents therapeutic use, Bisoprolol therapeutic use, Double-Blind Method, Female, Heart physiopathology, Heart Function Tests drug effects, Humans, Hypertension physiopathology, Kidney physiopathology, Kidney Function Tests, Losartan therapeutic use, Male, Middle Aged, Time Factors, Antihypertensive Agents pharmacology, Bisoprolol pharmacology, Heart drug effects, Hypertension drug therapy, Kidney drug effects, Losartan pharmacology
Abstract

Background and Objectives: Hypertension is a significant cause of chronic renal injury and its effective treatment is capable of reducing the rate of renal failure. beta-Adrenoceptor antagonists (beta-blockers) have been reported to induce a deterioration in renal function, while several data have indicated a renoprotective effect of treatment with the angiotensin II type 1 receptor antagonist losartan. Previous studies of the interaction between the selective beta(1)-blocker bisoprolol and kidney function were performed only for short- and medium-term periods. The aim of this study was to compare the antihypertensive efficacy and renal and cardiac haemodynamic effects of bisoprolol with those of losartan over a 1-year time period in patients with essential hypertension., Methods: Seventy-two patients (40 males) with recently diagnosed uncomplicated (European Society of Hypertension [ESH] criteria stage 1-2) hypertension (mean +/- SD age 52 +/- 12 years) were enrolled in the study. After a run-in period of 14 days on placebo, the patients were randomized in a double-blind, prospective study to receive either bisoprolol 5 mg or losartan 50 mg, administered once daily for 1 year. At recruitment and 12 months after treatment, cardiac output and renal haemodynamics and function were evaluated by echocardiography and radionuclide studies, respectively., Results: There were no significant differences in baseline clinical data, including glomerular filtration rate and blood pressure, between the two treatment groups. At 1 year, blood pressure had decreased significantly (p < 0.001) with both treatments, and heart rate was reduced only in the group taking bisoprolol. The long-term effects on renal haemodynamics and cardiac function were similar with both drugs, the only change being a significant reduction in the filtration fraction for each group., Conclusions: These data suggest that both bisoprolol and losartan are effective agents for the treatment of patients with recently diagnosed ESH stage 1-2 hypertension. Over a 1-year period, both agents maintained good renal and cardiac performance and haemodynamics.

Published
2009
Full Text
View/download PDF

13. The only good Helicobacter pylori is a dead Helicobacter pylori.

Author

Oderda G, Rapa A, Chiorbioli E, Caradonna M, and Bona G

Subjects
Adolescent, Antigens, Bacterial analysis, Bacterial Proteins analysis, Blotting, Western, Child, Child, Preschool, Female, Gastritis immunology, Humans, Male, Saliva microbiology, Sensitivity and Specificity, Gastritis microbiology, Helicobacter Infections immunology, Helicobacter Infections microbiology, Helicobacter pylori immunology
Published
1997
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results